PhD Scientific Days 2025

Theoretical and Translational Medicine I.

Investigating the effectiveness of incretin-based therapies in obesity-related obstructive sleep apnea

Előadó neve

Dr. Bardóczi Anna

Neptun code

IV5IVH

Előadó munkahelye

Department of Pulmonolgy, University of Semmelweis

Előadó telefonszáma

06208258841

Előadó e-mail címe

bardoczi.anna.boglarka@semmelweis.hu

Az előadás címe

Investigating the effectiveness of incretin-based therapies in obesity-related obstructive sleep apnea

Szerző(k) neve és munkahelye

Anna Bardóczi^1,2, Zsombor Matics^1,2, Caner Turan^2,3, Bence Szabó², Zsolt Molnár^2,3,4, Péter Hegyi^2,5,6, Veronika Müller^1,2, Gábor Horváth^1,2

1: Department of Pulmonolgy, University Semmelweis
2: Centre for Translational Medicine, Semmelweis University
3: Department of Anesthesiology and Intensive Therapy, Semmelweis University
4: Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences
5: Institute of Pancreatic Diseases, Semmelweis University
6: Institute for Translational Medicine, Medical School, University of Pécs

Bemutatás módja

Szóbeli

Szekció

Theoretical and Translational Medicine I.

Language of the presentation

Hungarian

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: Obstructive sleep apnea (OSA) significantly reduces quality of life and increases mortality, predominantly due to obesity. Conventional treatments, such as positive airway pressure (PAP), often have limited adherence. Incretin-based therapies, notably glucagon-like peptide-1 (GLP-1) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, offer promising obesity management options and thus represent potential treatments for OSA.

Aims: This systematic review and meta-analysis aimed to evaluate the efficacy of incretin-based therapies in reducing apnea-hypopnea index (AHI) and body weight in patients with obesity-related OSA.

Method: We conducted a systematic literature search in Medline, Embase, and Cochrane databases following PRISMA and Cochrane Handbook guidelines. Randomized controlled trials (RCTs) involving incretin-based therapies (liraglutide, tirzepatide) in adult patients with OSA were included. A meta-analysis using random-effects models assessed changes in AHI and body weight.

Results: Five articles reporting six RCTs with 1,024 patients met inclusion criteria. Incretin-based therapies significantly reduced AHI (mean change: -14.45 events/h; 95% CI: -25.90 to -2.99, p<0.001), demonstrating greater improvement compared to standard care (mean difference: -11.61 events/h; 95% CI: -22.91 to -0.31, p=0.046). Body weight decreased significantly with incretin therapies compared to standard care (mean difference: -11.4 kg; 95% CI: -21.93 to -0.88, p=0.041).

Conclusion: Incretin-based therapies effectively reduce body weight and significantly improve OSA severity, measured by AHI. These therapies hold potential as adjunctive or alternative treatments in obesity-related OSA management.

Funding: Funded by the Ph.D. program of the Centre of Translational Medicine, Semmelweis University. No external funders participated in study design or manuscript preparation.

University

Semmelweis University

Supervisor

Gábor Horváth

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

8374

Start

09:15

End

09:30